It hasn't quite been one year since Medigene AG made Dolores Schendel its CEO, consolidating its position as a fully immune-oncology focused biotech. However, the recent deal with bluebird bio Inc. will be seen as the official launch of Medigene as an anticancer player.
The deal is centered around Medigene's T cell receptor (TCR) discovery platform. The platform was one of three that the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?